Page 42 - Read Online

Page 152 Lotz et al. Cancer Drug Resist 2020;3:149-60 I http://dx.doi.org/10.20517/cdr.2019.114

Figure 2. Post-translational modifications of the human Top2a. Phosphorylations and acetylations identified in the recombinant
Top2a protein produced in yeast or mammalian cells are reported below the domain diagram (Bedez et al. [16] , 2018). Modifications
identified in cancer cells as reported in the PhosphoSiteplus database are indicated above the domain diagrams (Horneck et al. [40] ,
2014). Phosphorylation sites are colored in red, acetylation in blue, ubiquitination in yellow, and SUMOylation in green. To date,
about 104 phosphorylation, 28 acetylation, 67 ubiquitination, and 15 SUMOylation sites have been identified. Twenty-six out of 29
phosphorylations in normal cells and 46 out of 75 phosphorylations in cancer cells were found in the CTD. Fifteen SUMOylation sites
were identified in cancer cells, half on the DNA gate and C-gate, four in the N-gate, and five in the CTD. Thirteen acetylations on the
CTD and two in the ATPase domain were reported in cancer cells. Two phosphotyrosines were identified in the N-gate, three in the
DNA-gate, and one on the CTD in cancer cells. Positions are numbered as indicated in the NCBI gene ID:7153, which results in a +1 shift
in the residue numbering for some positions compared with their numbering in articles (for example, Thr1342 appears in the present
figure as Thr1343, and Ser1524 as Ser1525). Top2: type 2 DNA topoisomerase; CTD: C-terminal domain